Bruker Corporation · NASDAQ:BRKR
Bruker — Bruker BioSciences — Merger or Acquisition (December 2007)
22 slides from Bruker's merger presentation, Dec 3, 2007
Slide 1: Bruker BioSciences Announces Agreement to Acquire the Bruker BioSpin Group for $914 Million
Bruker BioSciences Corporation Announces Agreement to Acquire the Bruker BioSpin Group for $914 Million in Cash and Stock ADDITIONAL INFORMATION AND WHERE TO FIND IT THE TRANSACTIONS DESCRIBED IN THIS ANNOUNCEMENT HAVE NOT YET BEEN CONSUMMATED. BRUKER BIOSCIENCES AND ITS EXECUTIVE OFFICERS MAY BE DE
Slide 2: Presentation for BRKR Shareholders on Planned Acquisition of Bruker BioSpin Group
The planned combined Bruker Corporation (BRKR) Bruker BioSciences Corp. (NASDAQ: BRKR) & the private Bruker BioSpin Group (BBIO) Presentation for BRKR Shareholders on Planned Acquisition of Bruker BioSpin Group Frank H. Laukien, Chief Executive Officer Dirk Laukien, Senior Vice President William J.
Slide 3: BRKR Safe Harbor Statement
BRKR Safe Harbor Statement Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on curr
Slide 4: Presentation Overview
Presentation Overview Transaction Overview and Rationale Bruker BioSpin Highlights Planned Combined Bruker Corporation: Today & Tomorrow Note: This transaction is subject to BRKR shareholder approval, customary regulatory approvals and the completion of financing, and is expected to close in early 2
Slide 5: Transaction Overview and Rationale
Transaction Overview and Rationale 1) Expected to Create a Fast-Growing, High-Performance Leader A combined Bruker Corporation (BRKR) is expected to be close to a $1 Billion revenue company in 2008, providing high-performance scientific instrumentation and analytical solutions for life sciences, mat
Slide 6: Transaction Overview and Rationale
Transaction Overview and Rationale 4) Opportunities for synergistic value creation Leverage global marketing, sales & support, operational and financial synergies for growth Combined strategic initiative in clinical research systems, molecular diagnostics research and molecular imaging 5) Fixed Purc
Slide 7: Transaction Overview and Rationale
Transaction Overview and Rationale 6) Acquisition Financing New $380M 5-year senior credit facility to fund cash portion of the purchase price with JPMorgan and CitiBank as underwriters Multi-currency borrowings in USD, EUR and CHF available, initially at applicable LIBOR + 100 bps (initial EBITDA/d
Slide 8: Introduction and Overview
Bruker BioSpin Highlights Introduction and Overview Bruker founded in 1960 in Germany by Professor Guenther R. Laukien (in picture) Bruker BioSpin is the global market and technology leader in life science analytical instruments based on Magnetic Resonance including NMR, animal MRI and EPR Bruker Bi
Slide 9: Technology Platforms
Bruker BioSpin Highlights Technology Platforms 9 NMR – Determination and quantification of molecular structure and function based on intra-molecular environment MRI – Morphological, functional and molecular imaging for animal and translational MRI research EPR – Molecular structure determination bas
Slide 10: NMR: Nuclear Magnetic Resonance
10 Bruker BioSpin Highlights NMR: Nuclear Magnetic Resonance Customers: Academia & Industry Pharmaceutical and BioPharma Applications: Organic chemistry (structure elucidation) Inorganic Chemistry Protein Structures Structure-Activity relationships
Slide 11: MRI: Magnetic Resonance Imaging
11 Bruker BioSpin Highlights MRI: Magnetic Resonance Imaging Customers: Academia Research Hospitals Pharmaceutical Industry Applications: Preclinical studies on small animals Drug development Animal anatomy Molecular Imaging
Slide 12: EPR: Electron Paramagnetic Resonance
12 Bruker BioSpin Highlights EPR: Electron Paramagnetic Resonance Customers: Academia Government Labs Industry Applications: Spin Labels (structure elucidation) Inorganic chemistry Materials sciences
Slide 13: Superconducting Magnet Technology
Bruker BioSpin Highlights Superconducting Magnet Technology 13 In-house Superconducting Magnet Production and R&D capabilities for NMR, EPR, MRI, FTMS Laboratory Magnets of utmost strategic value for any magnetic resonance business
Slide 14: Superconducting Wire Technology
14 Bruker BioSpin Highlights Superconducting Wire Technology Advanced low-temperature superconducting wires for clinical MRI magnets, NMR magnets, FTMS magnets, as well as for magnets used in major accelerators or international research facilities, such as the ITER nuclear fusion project High-temper
Slide 15: The planned combined Bruker Corporation: Today & Tomorrow
The planned combined Bruker Corporation: Today & Tomorrow Commitment to innovation and growth Leading market position in key segments Attractive and diversified markets Significant synergies in growing markets Strong Bruker brand recognition among customers Positioned for further margin improvement
Slide 16: Bruker Corporation: History and Planned Combination in 2008
Bruker Corporation: History and Planned Combination in 2008 1960 Bruker was founded in 1960 with NMR products 2006 Bruker BioSciences acquires Bruker Optics 2003 Merger of Bruker Daltonics and Bruker AXS into Bruker BioSciences (BRKR) 1974 First Bruker FT-IR developed internally, basis for Bruker Op
Slide 17: Planned Bruker Corporation: a Global 'Critical Mass' Life Science Research and Analytical Solutions Company
Planned Bruker Corporation (BRKR): a Global ‘Critical Mass’ Life Science Research and Analytical Solutions Company Other Significant R&D and Production Sites Direct Sales Offices Major DE, CH & FR R&D and Production Sites Many additional distributors around the world Headquarters 17
Slide 18: BRKR and BBIO as Separate Companies: US GAAP Financial Highlights
BRKR and BBIO as Separate Companies: US GAAP Financial Highlights Pro forma historical combined financials will be filed in proxy statement with SEC. YTD YTD FY 2006 9/30/07 FY 2006 9/30/07 Revenue 435.8 $ 363.8 $ 447.0 $ 351.9 $ Growth Rate Y-O-Y 17.1% 21.2% 0.4% 12.2% Operating Income 30.7 26.2 76
Slide 19: Complementary Capabilities for Future Growth Markets
Complementary Capabilities for Future Growth Markets Organic and inorganic chemistry Expression proteomics and structural biology Pharma/biotech drug discovery and development Biomarker discovery, clinical proteomics and molecular diagnostics research Molecular imaging research in pathology and onco
Slide 20: Synergistic Opportunities for Additional Value Creation Between BRKR & BBIO
Synergistic Opportunities for Additional Value Creation Between BRKR & BBIO Leverage Global Marketing, Sales & Support Synergies for Growth Combined metabolomics, small molecule biomarker and applied analysis solutions Combined 3D molecular structure & function solutions Global, integrated customer
Slide 21: Financial Goals of planned Bruker Corporation for 2008 and Medium-Term
Financial Goals of planned Bruker Corporation for 2008 and Medium-Term (3-4 Years) Revenue Growth: 2008 goal: >8% growth Medium term goal: >10% growth mostly organic growth, selective acquisitions Gross Margin: 2008 goal: >46% GM Medium term goal: 50-100 bps improvement per year towards 48-49% GM RT
Slide 22: Bruker BioSciences
www.bruker.com Bruker BioSciences
Bruker BioSciences — Merger or Acquisition (December 2007) on 6ix